• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleared by FDA for Advanced Soft-Tissue Diagnostics

    3/9/26 8:30:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care
    Get the next $XRAY alert in real time by email

    Dentsply Sirona and Siemens Healthineers are pleased to announce that the first-ever dental-dedicated MRI1 (ddMRI) system – MAGNETOM Free.Max Dental Edition – has received FDA clearance in the United States. This milestone follows the completion of a clinical trial2 validating the system's significant potential across multiple dental specialties. The trial highlighted this first-of-its-kind technology's applicability in endodontics, periodontics, TMJ, tooth extraction, and orthodontics, offering non-ionizing imaging capabilities that can enhance diagnosis and treatment planning.

    CHARLOTTE, N.C., March 09, 2026 (GLOBE NEWSWIRE) -- Dentsply Sirona and Siemens Healthineers are pleased to share key findings from the clinical trial for validation of their dental-dedicated MRI system. In addition to confirming its significant potential across multiple dental specialties, the trial also underscored the ddMRI system's specialized features designed to meet the unique needs of dental professionals. Among these features is a dental-specific field of view, enabled by a dedicated dental coil and specialized software that focuses exclusively on dental structures, ensuring no brain tissue is visible and allowing for accurate imaging of dental structures. Additionally, the system's ability to streamline patient preparation and maintain an average workflow time of under 20 minutes3 makes it a highly efficient tool for clinical use.

    Clinical highlights from the trial demonstrated MAGNETOM Free.Max Dental Edition's ability to differentiate active inflammation from healthy and scar tissue, enable non-invasive assessment of tooth pulp vitality to support chairside testing and observations and enables the visualization of teeth and their position in relation to neighboring teeth as well as the nerves.

    "MAGNETOM Free.Max Dental Edition represents a significant advancement in dental imaging, providing excellent insights into dental structures that were not readily visible in other imaging modalities, without the risks associated with ionizing radiation. The ability to observe the same region of interest employing different ddMRI imaging sequences provides significantly more information regarding the pathological processes in hard and soft tissues which results in a more accurate understanding of the lesion. This capacity to see the clarity of the soft tissue detail produced by ddMRI has clear potential to enhance diagnostic confidence in areas where current modalities have limitations," said Prof. Don Tyndall, DDS, MSPH, PhD, FICD, FACD; Diplomate ABOMR, Professor of Diagnostic Sciences at University of North Carolina, who reviewed the clinical trial findings and collaborated in the FDA clearance process.

    Dental-dedicated MRI: excellent complement to existing imaging solutions

    As an ionizing radiation-free modality with advanced soft tissue contrast, ddMRI complements intraoral, panoramic, and CBCT imaging by addressing diagnostic questions where soft tissue characterization is critical.

    MAGNETOM Free.Max Dental Edition, the first-of-its-kind dental-dedicated MRI, was developed jointly by Dentsply Sirona, Siemens Healthineers, and leading scientists in Europe and the United States. Specifically designed to enhance dentomaxillofacial diagnostics, ddMRI is primarily intended for hospitals, large clinics, and universities, and offers advanced soft tissue contrast through ionizing radiation-free imaging.

    "This innovation is a powerful addition to our imaging portfolio, which includes Axeos, Orthophos SL, and Heliodent Plus, among others. We're proud to have contributed to developing the industry's first dental dedicated MRI and the advancement of diagnostic capabilities in the field," observed Dan Scavilla, President & CEO of Dentsply Sirona.

    "We are dedicated to expanding the clinical impact and reach of MRI. We are excited to see the potential of ddMRI being validated through clinical trials, which will pave the way for a new clinical field that will benefit dental practitioners and patients alike," said Andreas Schneck, head of Magnetic Resonance at Siemens Healthineers.

    Advanced Clinical Training Opportunity

    Clinicians interested in incorporating ddMRI into their practice can participate in an advanced, hands‑on training program taking place in April 2026 at the University of Minnesota. This two‑day course covers ddMRI imaging protocols, recommended clinical procedures, essential MR facility and patient safety guidelines, hands‑on image acquisition, and practical interpretation sessions featuring TMJ and dental cases.

    For more details, please visit Introduction to Dental MRI: A Hands‑on Program | School of Dentistry.

    Learn more at the upcoming American Dental Education Association (ADEA) Annual Session

    Visit the Dentsply Sirona booth at the American Dental Education Association (ADEA 2026) Annual Session, taking place March 21–24 in Montréal, Canada, and learn more about the first dental-dedicated magnetic resonance imaging (ddMRI) system.

    Learn more at www.dentsplysirona.com/ddmri

    Registered brands, trade names and logos are used. Even in particular cases, when they appear without a TM or ®, all corresponding legal rules and provisions apply. All rights are retained by Dentsply Sirona. Clinicians may have been compensated for use of their experiences and testimonials.

    About Dentsply Sirona

    Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona's innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company's shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

    Contact Information:

    Dentsply Sirona Press Contact:

    Marion Par-Weixlberger

    Vice President, Public Relations, Corporate Communications & Brand

    Publicrelations@dentsplysirona.com | www.dentsplysirona.com

    Siemens Healthineers Press Contact:

    Stefanie Haug | Magnetic Resonance Imaging, Computed Tomography and X-ray

    +49 173 6358240 | stefanie.haug@siemens-healthineers.com

    1 The product mentioned here is not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed.

    2 Clinical Evaluation Report, MAGNETOM Free.Max Dental Edition, 2025. Copyright@Siemens Healthineers. Data on file.

    3 Greiser et al. (2023): Dental-dedicated MRI, a novel approach for dentomaxillofacial diagnostic imaging: technical specifications and feasibility, in: Dentomaxillofacial Radiology, 2023, 00, 1-12



    Primary Logo

    Get the next $XRAY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XRAY

    DatePrice TargetRatingAnalyst
    4/15/2026$10.00Sell
    Citigroup
    2/19/2026$17.00Neutral → Buy
    BofA Securities
    12/9/2025$12.00Underweight
    Barclays
    11/7/2025Outperform → Mkt Perform
    William Blair
    4/15/2025$14.00Overweight → Equal-Weight
    Morgan Stanley
    3/13/2025Buy → Hold
    Needham
    2/14/2025$20.00Equal Weight
    Wells Fargo
    1/23/2025$30.00 → $20.00Buy → Hold
    Jefferies
    More analyst ratings

    $XRAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dentsply Sirona Continues to Expand U.S. Distribution Network to Strengthen Access to its Digital Dentistry Solutions Across Key Regional Markets

    CHARLOTTE, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Dentsply Sirona (NASDAQ:XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced the strengthening of its U.S. distribution footprint through an expanded partnership with Nashville Dental, Inc (NDI), a leading independent dental distributor serving the Southeast and Mid-Atlantic regions. As of August 1, 2026, NDI's portfolio will include Dentsply Sirona's full range of connected technology solutions, including the CEREC system, Primescan intraoral scanners, and digital imaging solutions. This expansion allows dental practices across a nine-state territory to access the company's

    5/26/26 4:30:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona to Participate in the 2026 Stifel Jaws & Paws Conference

    CHARLOTTE, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will participate in the 2026 Stifel Jaws & Paws Conference. Management is scheduled to present on Wednesday, May 27, 2026, at 3:35 p.m. ET. Investors and other interested parties will be able to access a live audio webcast and an audio webcast replay by visiting the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to

    5/20/26 4:15:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Reports First Quarter 2026 Results

    News Summary Reported net sales of $880 millionDelivered GAAP gross margin of 48.5%, GAAP net loss per share of ($0.05)Achieved adjusted gross margin of 50.7%, adjusted EBITDA margin of 14.7%, adjusted EPS of $0.27Launched Smart View-Detect, the world's first FDA-cleared, AI-enabled diagnostic aid designed to identify teeth with periapical radiolucencies (PARL) in CBCT scans, now also CE-marked for use across EuropeContinued to penetrate connected technology solutions market with new Atlanta Dental Supply distributor agreementInstalled first CEREC® system under the new Benco Dental distribution agreement, marking an important early milestoneBegan implementing new capital allocation strategy

    5/5/26 4:01:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lucier Gregory T bought $186,675 worth of shares (15,000 units at $12.45) (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/9/26 4:20:49 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Director Forbes James D bought $62,400 worth of shares (5,000 units at $12.48), increasing direct ownership by 100% to 10,000 units (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/9/26 4:19:42 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Director Lucier Gregory T bought $707,379 worth of shares (50,000 units at $14.15) (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/3/26 7:12:19 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    SEC Filings

    View All

    DENTSPLY SIRONA Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

    6/4/26 4:23:44 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by DENTSPLY SIRONA Inc.

    SD - DENTSPLY SIRONA Inc. (0000818479) (Filer)

    6/1/26 6:01:20 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by DENTSPLY SIRONA Inc.

    10-Q - DENTSPLY SIRONA Inc. (0000818479) (Filer)

    5/5/26 4:50:02 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Dentsply Sirona with a new price target

    Citigroup initiated coverage of Dentsply Sirona with a rating of Sell and set a new price target of $10.00

    4/15/26 8:07:52 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona upgraded by BofA Securities with a new price target

    BofA Securities upgraded Dentsply Sirona from Neutral to Buy and set a new price target of $17.00

    2/19/26 7:47:02 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on Dentsply Sirona with a new price target

    Barclays initiated coverage of Dentsply Sirona with a rating of Underweight and set a new price target of $12.00

    12/9/25 8:44:01 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CEO & Member of BOD Scavilla Daniel T covered exercise/tax liability with 4,095 shares, decreasing direct ownership by 3% to 157,754 units (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    5/26/26 6:04:28 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Mazelsky Jonathan Jay

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    4/2/26 5:09:02 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by President, CEO & Member of BOD Scavilla Daniel T

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/12/26 5:44:35 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Leadership Updates

    Live Leadership Updates

    View All

    Dentsply Sirona Appoints James Forbes and Brian McKeon to Board of Directors

    CHARLOTTE, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) --  DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced the appointments of James (Jim) D. Forbes and Brian P. McKeon to its Board of Directors (the "Board"), effective February 27, 2026. Mr. Forbes is a veteran healthcare investment banker with 30 years of experience helping companies develop strategies to drive profitable growth and long-term value creation. Mr. Forbes is widely recognized for advising healthcare companies on complex strategic transactions and capital markets engagements. He most recently served as Vice Chairman of Investment Banking at Morgan Stanley, and he previously held senior execu

    2/24/26 4:30:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Appoints Donald Zurbay to Board of Directors

    CHARLOTTE, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced the appointment of Donald (Don) Zurbay to its Board of Directors (the "Board"), effective January 10, 2026. He will be joining the Board's Audit and Finance Committee. Mr. Zurbay brings extensive leadership experience in the dental and healthcare industries, and value creation across complex, global organizations. He most recently served as President and Chief Executive Officer (CEO) of Patterson Companies, following his tenure as Chief Financial Officer (CFO) from 2018 to 2022. During his tenure, Patterson maintained a longstanding dealer partnership

    1/13/26 8:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Appoints Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization

    CHARLOTTE, N.C., Jan. 12, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced the appointment of Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization, effective January 28. The appointment supports Dentsply Sirona's continued focus on strengthening commercial execution, deepening customer relationships and accelerating growth across the Americas. Mr. Bezjak is a seasoned commercial executive with more than 20 years of experience leading large-scale, multi-billion-dollar organizations in the medical device

    1/12/26 9:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DENTSPLY SIRONA Inc.

    SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)

    12/6/24 10:11:29 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

    SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

    11/14/24 1:22:35 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

    SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

    11/12/24 4:23:31 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Financials

    Live finance-specific insights

    View All

    Dentsply Sirona Reports First Quarter 2026 Results

    News Summary Reported net sales of $880 millionDelivered GAAP gross margin of 48.5%, GAAP net loss per share of ($0.05)Achieved adjusted gross margin of 50.7%, adjusted EBITDA margin of 14.7%, adjusted EPS of $0.27Launched Smart View-Detect, the world's first FDA-cleared, AI-enabled diagnostic aid designed to identify teeth with periapical radiolucencies (PARL) in CBCT scans, now also CE-marked for use across EuropeContinued to penetrate connected technology solutions market with new Atlanta Dental Supply distributor agreementInstalled first CEREC® system under the new Benco Dental distribution agreement, marking an important early milestoneBegan implementing new capital allocation strategy

    5/5/26 4:01:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona to Host First Quarter 2026 Conference Call on May 5

    CHARLOTTE, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will host an investor conference call and live webcast on Tuesday, May 5, 2026, at 4:30 p.m. ET to review its first quarter 2026 financial results. Financial earnings materials will be made available on the Investors section of the Company's website at https://investor.dentsplysirona.com prior to the call. Conference Call / Webcast Information The live webcast link and call information will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. For those planning to participate on the c

    4/22/26 4:15:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook

    News Summary Q4 2025 net sales of $961 million increased 6.2%, constant currency sales increased 2.5%Q4 2025 reported net loss of ($146) million and diluted loss per share of ($0.74) driven by goodwill and intangible impairments of ($144) million, net of taxQ4 2025 adjusted EPS of $0.27FY 2026 outlook: net sales in the range of $3.5B to $3.6B; adjusted EPS of $1.40 to $1.50(1)Announced a restructuring initiative to redirect approximately $120 million annually into the Return-to-Growth Action Plan, prioritizing investments in accelerated innovation, clinical education, and sales team education focused on connected dentistryInitiated new capital allocation strategy by eliminating the dividend

    2/26/26 4:01:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care